Targeting HDAC/OAZ1 axis with a novel inhibitor effectively reverses cisplatin resistance in non-small cell lung cancer

Cisplatin yields significant efficacy and is generally used as a frontline therapy for non-small cell lung cancer (NSCLC). However, acquired resistance strongly limits its application. Here, we identified that a novel histone deacetylase (HDAC) inhibitor S11, with P-glycoprotein inhibitory activity,...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cell Death Dis
Hoofdauteurs: Sun, Yuhong, Bao, Xuefei, Ren, Yong, Jia, Lina, Zou, Shenglan, Han, Jian, Zhao, Mengyue, Han, Mei, Li, Hong, Hua, Qixiang, Fang, Yi, Yang, Jingyu, Wu, Chunfu, Chen, Guoliang, Wang, Lihui
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Nature Publishing Group UK 2019
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6534535/
https://ncbi.nlm.nih.gov/pubmed/31127087
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-019-1597-y
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items